Gene modified therapy: No investigational cell product will be administered
Study summary
Long-term follow-up of study subjects who received AGT103-T product in HIV study. The AGT103-T is genetically modified cells that resist infection with HIV causing a depletion of HIV in HIV-infected study participants.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
1. Received the investigational product, AGT103-T, in the AGT-sponsored AGT-HC168 clinical trial
2. Provided written informed consent, signed and dated by the study participant in the long-term follow-up study
Exclusion Criteria:
1\. Did not receive the investigational product, AGT103-T
Primary outcome measure(s)
Assess the incidence of delayed adverse events (AE) to gene therapy — 1year to 15years post infusion The presence of malignancies, incidence or exacerbation of pre-existing neurologic disorder, new incidence or exacerbation of a prior rheumatologic or other autoimmune disorder, the new incidence of a hematologic disorder post infusion with AGT103T
Trial sites (2)
Facility
City
Region
Status
Georgetown University
Washington D.C.
District of Columbia
Washington Health Institute
Washington D.C.
District of Columbia
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.